Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan;10(1):45-57.
doi: 10.2217/whe.13.72.

Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer

Jonathan D Black  1 , Diana P English, Dana M Roque, Alessandro D Santin
Affiliations
Review

Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer

Jonathan D Black et al. Womens Health (Lond). 2014 Jan.

Abstract

Uterine serous carcinoma (USC) is a highly aggressive variant of endometrial cancer. Although it only represents less than 10% of all cases, it accounts for a disproportionate number of deaths from endometrial cancer. Comprehensive surgical staging followed by carboplatin and paclitaxel chemotherapy represents the mainstay of USC therapy. Vaginal cuff brachytherapy is also of potential benefit in USC. Recent whole-exome sequencing studies have demonstrated gain of function of the HER2/NEU gene, as well as driver mutations in the PIK3CA/AKT/mTOR and cyclin E/FBXW7 oncogenic pathways in a large number of USCs. These results emphasize the relevance of these novel therapeutic targets for biologic therapy of chemotherapy-resistant recurrent USC.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Targeted therapy in uterine serous carcinoma.
(A) HER2 antibodies and anti-HER2 vaccines, (B) antibody–drug conjugate, (C) tyrosine kinase inhibitors, (D) PI3K/AKT/mTOR pathway inhibitors, (E) monoclonal antibodies and small-molecule inhibitors, (F) Clostridium perfringens toxin-based therapeutic approaches and (G) CDK inhibitors and curcumin. VEGFR: VEGF receptor.
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012;62(1):10–29. - PubMed
    1. Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with type I and type II endometrial cancer. Cancer Causes Control. 2010;21(11):1851–1856. - PMC - PubMed
    1. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 2006;95(Suppl. 1):S105–S143. - PubMed
    1. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Comparison of estrogen and progesterone receptor, Ki-67, and P53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. Hum. Pathol. 1998;29(9):924–931. - PubMed
    1. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol. Oncol. 1994;54(3):264–268. - PubMed

Websites

    1. Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer. http://clinicaltrials.gov/show/NCT01367002.
    1. Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer. http://clinicaltrials.gov/show/NCT00977574.
    1. Safety Study of 212Pb-TCMC-Trastuzumab Radio Immunotherapy. http://clinicaltrials.gov/show/NCT01384253.
    1. Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma. http://clinicaltrials.gov/show/NCT00513786.
    1. VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer. http://clinicaltrials.gov/show/NCT00462826.

Publication types

MeSH terms